Assessment and management of antipsychotic-induced adverse events

被引:11
作者
Cortese, L
Pourcher-Bouchard, E
Williams, R
机构
[1] London Hlth Sci Ctr, Dept Psychiat, London, ON N6A 4G5, Canada
[2] Univ Western Ontario, Dept Psychiat, London, ON N6A 3K7, Canada
[3] Univ Laval, Laval, PQ, Canada
[4] Hop Enfants Jesus, Clin Troubles Mouverment, Quebec City, PQ, Canada
[5] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada
[6] Royal Jubilee Hosp, Schizophrenia Serv, Victoria, BC, Canada
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 1998年 / 43卷
关键词
psychosis; antipsychotics; adverse events; treatment;
D O I
10.1177/07067437980430S105
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To review and discuss the spectrum of adverse events caused by antipsychotic agents that can directly influence the outcome of treatment by interfering with patient acceptance of and adherence to therapy. Method: The adverse effects of traditional and second-generation antipsychotic medications were discussed during a series of clinical workshops attended by psychiatrists from across Canada. The various adverse effects of antipsychotic drugs as well as their assessment and management are reviewed Results: Simple techniques for assessing adverse effects such as extrapyrimidal symptoms (EPS) are described. In some cases, adverse effects can be managed by dosage reduction and/or the use of adjunctive therapies such as antiparkinsonian agents and benzodiazepines. However, in some patients dose reduction carries the risk of symptom reemergence, while the commonly used adjunctive medications are associated with adverse effects of their own. Conclusions: Treatment-related side effects often require a reduction in dosage or a change in medication. Proper management can help encourage patient compliance and improve the outcome of antipsychotic treatment. The availability of the newer atypical antipsychotics offers another alternative, because they are associated with a much lower incidence of antipsychotic-induced side effects.
引用
收藏
页码:15S / 20S
页数:6
相关论文
共 44 条
[31]  
Marder S R, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p92A
[32]  
MCCARLEY RW, 1989, ARCH GEN PSYCHIAT, V46, P698
[33]   RISPERIDONE IN THE TREATMENT OF PATIENTS WITH CHRONIC-SCHIZOPHRENIA - A MULTI-NATIONAL, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP STUDY VERSUS HALOPERIDOL [J].
PEUSKENS, J .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 166 :712-726
[34]   INCREASED CONCENTRATIONS AND LATERAL ASYMMETRY OF AMYGDALA DOPAMINE IN SCHIZOPHRENIA [J].
REYNOLDS, GP .
NATURE, 1983, 305 (5934) :527-529
[35]  
RISCH SC, 1981, J CLIN PSYCHIAT, V42, P47
[36]   NEUROLEPTIC MALIGNANT SYNDROME - REVIEW OF RESPONSE TO THERAPY [J].
ROSENBERG, MR ;
GREEN, M .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (09) :1927-1931
[37]  
Shriqui Christian L., 1995, P585
[38]   Extrapyramidal symptoms in patients treated with risperidone [J].
Simpson, GM ;
Lindenmayer, JP .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (03) :194-201
[39]  
THAKER GK, 1990, AM J PSYCHIAT, V147, P445
[40]  
VANKAMMEN DP, 1995, COMPREHENSIVE TXB PS, V2, P1979